AU2003237686A1 - Rna interference mediating small rna molecules - Google Patents
Rna interference mediating small rna moleculesInfo
- Publication number
- AU2003237686A1 AU2003237686A1 AU2003237686A AU2003237686A AU2003237686A1 AU 2003237686 A1 AU2003237686 A1 AU 2003237686A1 AU 2003237686 A AU2003237686 A AU 2003237686A AU 2003237686 A AU2003237686 A AU 2003237686A AU 2003237686 A1 AU2003237686 A1 AU 2003237686A1
- Authority
- AU
- Australia
- Prior art keywords
- rna
- interference mediating
- mediating small
- molecules
- rna molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38298302P | 2002-05-24 | 2002-05-24 | |
US60/382,983 | 2002-05-24 | ||
PCT/EP2003/005513 WO2003099298A1 (en) | 2002-05-24 | 2003-05-26 | Rna interference mediating small rna molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003237686A1 true AU2003237686A1 (en) | 2003-12-12 |
Family
ID=29584485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003237686A Abandoned AU2003237686A1 (en) | 2002-05-24 | 2003-05-26 | Rna interference mediating small rna molecules |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003237686A1 (en) |
WO (1) | WO2003099298A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2336887T5 (en) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediators of RNA interference specific to RNA sequences |
EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1476459A4 (en) * | 2002-02-20 | 2005-05-25 | Sirna Therapeutics Inc | RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
US20070254850A1 (en) * | 2002-10-30 | 2007-11-01 | Judy Lieberman | Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents |
EP2000160A3 (en) | 2002-10-30 | 2009-03-11 | Gambro Lundia AB | Method and apparatuses for determining the efficiency of dialysis |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
CA2513623A1 (en) | 2003-01-16 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of icam-1 |
US7732591B2 (en) | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
JP2004261026A (en) * | 2003-02-28 | 2004-09-24 | Institute Of Physical & Chemical Research | Double-stranded rna oligonucleotide having expression inhibitory action on cyclin b gene |
AU2004233043A1 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
AU2004255557B2 (en) * | 2003-06-09 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
EP3604537B1 (en) | 2003-06-13 | 2021-12-08 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
EP1694839A2 (en) * | 2003-12-12 | 2006-08-30 | Novo Nordisk A/S | Laminin-5 modulators and uses thereof |
WO2005062957A2 (en) | 2003-12-23 | 2005-07-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
FR2864960A1 (en) * | 2004-01-14 | 2005-07-15 | Univ Rennes | Double-stranded interfering RNA, and vectors containing it, useful for treatment of cancer, modulate expression of the ERK2 protein and thus cell proliferation |
US20060058255A1 (en) * | 2004-03-01 | 2006-03-16 | Jianzhu Chen | RNAi-based therapeutics for allergic rhinitis and asthma |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1765847A4 (en) | 2004-05-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | Nuclease resistant double-stranded ribonucleic acid |
US7297786B2 (en) | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
DE102005003788A1 (en) | 2005-01-19 | 2006-07-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | siRNA molecules for the treatment of blood vessels |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
WO2008055530A1 (en) * | 2006-11-09 | 2008-05-15 | Unibioscreen S.A. | Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases |
WO2008148304A1 (en) * | 2007-05-31 | 2008-12-11 | Xiamen University | Rna interference target for treating aids |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
EP2361306A1 (en) | 2008-12-04 | 2011-08-31 | OPKO Ophthalmics, LLC | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2011032100A1 (en) | 2009-09-11 | 2011-03-17 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of kshv vil6 and human il6 |
WO2012051491A1 (en) | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
PL2897620T3 (en) | 2012-09-21 | 2020-11-02 | Intensity Therapeutics, Inc | Method of treating cancer |
WO2014055825A1 (en) | 2012-10-04 | 2014-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A formulation of mycobacterial components as an adjuvant for inducing th17 responses |
US10258682B2 (en) | 2013-01-16 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Attenuated chlamydia vaccine |
WO2017106171A1 (en) * | 2015-12-14 | 2017-06-22 | The Regents Of The University Of California | Rna interference for control of insect pests |
AU2017224113B2 (en) | 2016-02-25 | 2022-04-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
US20170360815A1 (en) | 2016-02-25 | 2017-12-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
KR102256001B1 (en) * | 2019-07-02 | 2021-05-26 | 주식회사 엔에이백신연구소 | Novel ribonucleic acid and pharmaceutical composition based on the same |
CN114761558A (en) * | 2019-07-02 | 2022-07-15 | 株式会社Na疫苗研究所 | Novel ribonucleic acid and pharmaceutical compositions based thereon |
CN111763669B (en) * | 2020-02-10 | 2021-06-15 | 澳门科技大学 | Double-stranded RNA molecule and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2336887T5 (en) * | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediators of RNA interference specific to RNA sequences |
EP1873259B1 (en) * | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
-
2003
- 2003-05-26 WO PCT/EP2003/005513 patent/WO2003099298A1/en not_active Application Discontinuation
- 2003-05-26 AU AU2003237686A patent/AU2003237686A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003099298A1 (en) | 2003-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003237686A1 (en) | Rna interference mediating small rna molecules | |
AU2003295539A1 (en) | Allele-targeted rna interference | |
HUP0302557A3 (en) | Rna interference mediating small rna molecules | |
AU2003299531A1 (en) | Compounds for modulating rna interference | |
AU2003288304A1 (en) | Novel molecules derived from noraporphine | |
AU2003303586A1 (en) | Methods for attaching molecules | |
AU2003272930A1 (en) | Footwere | |
AU2003902455A0 (en) | Cadmas | |
AU2002245332A1 (en) | Anergy-regulated molecules | |
AU2002337312A1 (en) | Molecules | |
EP1572168A3 (en) | Anti-infarction molecules | |
AU2003274573A1 (en) | Deburrer | |
AU2003212825A1 (en) | Aggrecanase molecules | |
AU2003276655A1 (en) | Pi - conjugated molecules | |
AU2003241762A1 (en) | Dna shuflling | |
AU2003241210A1 (en) | Videocomputer | |
AU2002952545A0 (en) | Nucleic acid molecules | |
AU2003100325A4 (en) | Freez-A-Cube | |
AU2003100198A4 (en) | Colourband Browbands | |
AU2003100378A4 (en) | Scootermansydney | |
AU2003100942A4 (en) | Energenz | |
AU2003906925A0 (en) | Transfer of molecules | |
AU2003906486A0 (en) | Antiflame coating | |
AU2003904694A0 (en) | Purifying molecules | |
AU2003900437A0 (en) | Immunointeractive molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |